Egypt’s Audit Watchdog Issues Qualified Opinion on Nile Pharmaceuticals’ Accounts

Egypt’s Central Auditing Organization has issued a qualified opinion on the financial statements of Nile Pharmaceuticals for the fiscal year ended June 30, 2026, after identifying accounting concerns.

The reservations included issues involving scrap assets and the dollar exchange rate used in the accounts. The available summary did not specify the assets concerned or the exchange rate applied.

A qualified opinion indicates that an auditor has reservations about particular aspects of financial statements, rather than rejecting the accounts as a whole.

The summary did not detail the financial impact of the findings or include a response from Nile Pharmaceuticals on whether it would make adjustments.